SCHEMBL3024196

SCHEMBL3024196

Cc1ccc(C(=O)Nc2cccc(C(F)(F)F)c2)cc1Nc1ncnn1-c1cc(NC2CC2)ncn1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LCK P06239 12/20 0.62
KDR P35968 11/20 0.62
LYN P07948 10/20 0.62
SRC P12931 10/20 0.62
INSR P06213 8/20 0.62
HCK P08631 6/20 0.62
POLB P06746 2/20 0.55
MAPT P10636 1/20 0.55
APEX1 P27695 1/20 0.55
MAPK14 Q16539 2/20 0.51
KIT P10721 1/20 0.51
EPHB2 P29323 1/20 0.51
DDR1 Q08345 1/20 0.51
DDR2 Q16832 1/20 0.51
ABL1 P00519 1/20 0.51
BRAF P15056 3/20 0.50
TEK Q02763 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020295 0.95 LCK (0.67) LCKKDRLYNSRCINSR
SCHEMBL3021652 0.90 POLB (0.59) LCKKDRLYNSRCINSR
SCHEMBL13269702 0.87 LCK (0.61) LCKKDRLYNSRCINSR
SCHEMBL3015323 0.86 LCK (0.60) LCKKDRLYNSRCINSR
SCHEMBL3022304 0.86 ABL1 (0.55) LCKKDRLYNSRCINSR
SCHEMBL3009202 0.85 RAF1 (0.57) LCKKDRLYNSRCINSR
SCHEMBL3015220 0.85 LCK (0.66) LCKKDRLYNSRCINSR
SCHEMBL3016586 0.85 BRAF (0.57) LCKKDRLYNSRCINSR
SCHEMBL3011048 0.84 BRAF (0.56) LCKKDRLYNSRCINSR
SCHEMBL3014317 0.84 BRAF (0.54) LCKKDRLYNSRCINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US claimed
EP-2170867-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2010-04-07 EP claimed
WO-2008157131-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2008-12-24 WO claimed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
EP-2170867-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2010-04-07 EP disclosed
WO-2008157131-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof BMX, FRK, FYN LCK 8/4885KDR 182/4885LYN 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.